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【Introduction】  
Lung cancer is the leading cause of cancer death in the world. Smoking is the most important risk 
factor for lung cancer, but lung cancers arising in never smokers have increased in recent times. These 
findings suggest that additional factors other than smoking may have an impact as etiological and risk 
factors for lung cancer.  
In 2008, a new human tumor virus, Merkel cell polyomavirus (MCPyV), was discovered as a 
causative agent of Merkel cell carcinoma (MCC), a neuroendocrine carcinoma of the skin. While the 
route of MCPyV transmission has not been established, detection of MCPyV DNA fragments in 
respiratory tract secretions was reported in 2010. It is likely that long-term exposure of the respiratory 
tract to this oncogenic virus may cause the cancer in this region. Based on the histological similarities 
between MCC and small-cell lung cancer (SCLC), the possible association between MCPyV and 
SCLC has been reported previously. However, the prevalence of MCPyV in non-small cell lung 
cancer (NSCLC) has not been studied well. This study was performed to determine the possible viral 
etiology of NSCLCs among Japanese subjects. 
 
【Materials and Methods】  
Patients and samples 
This study included 112 Japanese patients with primary resectable NSCLC, including 32 squamous 
cell carcinomas (SCCs), 45 adenocarcinomas (ACs), 32 large-cell carcinomas including 19 large-cell 
neuroendocrine carcinomas (LCNECs) and 3 pleomorphic carcinomas. Surgically resected frozen 
tumor samples were obtained from the archives of Kochi University Hospital.   
Detection of MCPyV DNA with standard PCR 
Standard PCR was performed with 200 ng of extracted DNA from the frozen tissue samplers using 
three primer sets, commonly used to detect the MCPyV large T (LT) and viral protein 1 (VP1) genes.  
Quantification of MCPyV DNA with real-time PCR 
MCPyV-positive samples identified by standard PCR were subjected to a quantitative real-time PCR 
analysis to determined MCPyV DNA loads. The reactions were performed with 200 ng of extracted 
DNA using specific labeled probe and primers targeting the MCPyV small T antigen (ST) gene. 
Reverse transcription (RT)-PCR 
RT-PCR was performed on total RNA extracted from the frozen biopsy specimens. Specific primers 
for analysis of cDNA were used to determine the MCPyV LT and VP1 gene expressions.  
Immunohistochemistry 
For detecting the MCPyV antigen, immunohistochemistry was performed on formalin-fixed 
paraffin-embedded tissue sections using a monoclonal antibody targeted to the MCPyV LT antigen.  
Analysis of the MCPyV integration site 
The integration sites of MCPyV were determined using the DIPS-PCR technique (detection of 
integrated papilloma sequences).  
 
【Results and Discussion】 
MCPyV was detected in 9/32 (28.1%) tissue samples of SCCs, 9/45 (20.0%) of ACs, 1/32 (3.1%) of 
large-cell carcinomas (including one MCPyV-positive LCNEC), and 1/3 (33.3%) of PL by standard 
PCR. In total, 20 of 112 NSCLC (17.9%) tissue samples were positive for MCPyV DNA. These 
results were close to the results reported from North America, but different from those from Chile. 
The differences in the detection rates may be explained in part by geographic epidemiological 
diversities in patients with NSCLCs or by the technical approaches used. 
The viral DNA loads ranged from 0.0001 to 0.026 copies per cell, shown by quantitative real-time 
PCR. These DNA loads were lower than those in MCPyV-positive Japanese MCC cases. 
Several oncogenic mechanisms for MCPyV development have been proposed in 
MCPyV-positive-MCC: (1) expression of the MCPyV oncogenic protein, LT antigen; (2) loss of viral 
replication capacity; and (3) tumor-specific mutations, including the truncating mutation of the LT 
gene and integration of the viral genome into host chromosome.  
Expression of the MCPyV LT antigen was examined at the RNA and protein levels by RT-PCR and 
immunohistochemistry, respectively. The MCPyV LT gene transcript was found in 4/10 of 
MCPyV-positive samples which were suitable for RNA extraction in MCPyV-positive tumors, 
whereas no VP1 gene transcript was found in any samples. As the results of immunohistochemistry, 
strong diffuse or speckled nuclear signals were observed in tumor cells, indicating that these cancer 
cells expressed the LT antigen. During viral replication, MCPyV has an orderly gene expression 
cascade in which the LT gene transcript is expressed first (early gene transcription), followed by the 
expression of the VP1 gene (late gene transcription). Accordingly, these results suggested that our 
MCPyV-positive NSCLC tumors had no viral replication activity. 
To evaluate integration status of MCPyV, DIPS-PCR was performed. The MCPyV integration was 
demonstrated in 2 cases, in which the viral genomes were inserted into chromosome 5 and 
chromosome 11, respectively. Additionally, the virus-host junctions in these cases were both located 
in the MCPyV LT gene, generating the truncated LT gene. 
 
【Conclusion】  
This study provided the first evidence of prevalence of MCPyV in NSCLCs among Japanese 
subjects. Furthermore, this study demonstrated the integrated/mutated forms as a tumor-specific 
signature of MCPyV for the first time in a specific cancer other than MCC. Although the prevalence 
of MCPyV and viral loads in our NSCLCs were low as compared with those in MCPyV-positive 
MCCs, our findings suggest that MCPyV is associated with the pathogenesis of NSCLC in a subset of 
patients.  
